TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05320094
Drug: Activated Charcoal with Sorbitol
Normalized name: Activated Charcoal with Sorbitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05600114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID
Study: NCT05132049
Drug: DA-5211-R1 + DA-5211-R2
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (DA-5211-R1 one tablet once a day + DA-5211-R2 one tablet once a day)
Study: NCT06562907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05157113
Drug: Dropless Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative subconjunctival injection of triamcinolone acetonide (20mg) delivered 4-5 mm posterior to the limbus at the end of surgery.~Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~No postoperative drops.
Study: NCT04758949
Drug: FL-101
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg administered intravenously every 2 weeks prior to surgery.
Study: NCT04758949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg administered intravenously every 2 weeks prior to surgery.
Study: NCT04860505
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline (DOX \[200 mg\]) is an oral medication used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections.
Study: NCT04767815
Drug: Diet B group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minutes after a high-fat meal + DWN12088 200 mg
Study: NCT05782894
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5\~12μg/kg/h
Study: NCT06461390
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NE Group (Fluid loading with early norepinephrine administration group) NE Group will receive ringer lactate bolus 20 ml/kg along with norepinephrine infusion at 0.1 mcg/kg/minute until MAP\&gt;5 percentile. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed, with or without continued norepinephrine infusion according to the treatment group
Study: NCT05957510
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: the treatment recommended by the investigator
Study: NCT06427590
Drug: ASC47
Normalized name: Ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single subcutaneous injection of ASC47
Study: NCT06427590
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single subcutaneous injection of Placebo
Study: NCT05517655
Drug: 129Xe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation.
Study: NCT06025344
Drug: PanCytoVir™ 100 mg/mL oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 1000 mg (100 mg/mL) under fasted conditions
Study: NCT06101927
Drug: Whole body study and SPECT with [99mTc]Tc-BQ0413
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single intravenous injection of \[99mTc\]Tc-BQ0413, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
Study: NCT04815993
Drug: SYN-020 delayed release capsule
Normalized name: Gel-Syn
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.
Study: NCT04763759
Drug: TRL1068, a human monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
Study: NCT05077475
Drug: C52R1H Tab. and C52R2 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose C52R1H(FDC, Valsartan/Amlodipine) 160/10 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
Study: NCT05077475
Drug: AJU-C52L
Normalized name: AJUGA REPTANS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 80/5/12.5 mg FDC 2 tablet
Study: NCT06082635
Drug: TGRX-326
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated with the investigational drug TGRX-326 at 60 mg once a day in 28-day cycles
Study: NCT06064669
Drug: Metformin pretreatment before ovarian stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
Study: NCT06064669
Drug: Placebo pretreatment before ovarian stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
Study: NCT06064669
Drug: Metformin pretreatment before endometrial preparation for frozen embryo transfer
Normalized name: human embryo tissue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: After oocyte retrieval, the enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
Study: NCT06064669
Drug: Placebo pretreatment before endometrial preparation for frozen embryo transfer
Normalized name: human embryo tissue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: After oocyte retrieval, the enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
Study: NCT06109454
Drug: Huaier granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects voluntarily gave up postoperative adjuvant therapy, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, and agreed to take Huaier granules.The subjects took Huaier granules orally, one bag (10g) per time, three times a day. Until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or when the researcher determines that there is no further benefit, whichever occurs first. Please refer to the drug manual for specific usage. It is recommended that patients start taking Huaier granules 1-2 weeks after surgery.
Study: NCT05408091
Drug: TRL345, a human monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Human Cytomegalovirus (HCMV) IgG1κ Human Monoclonal Antibody
Study: NCT06601504
Drug: HMPL-760 planned dose 1
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HMPL-760 planned dose 1 daily (QD) orally
Study: NCT06601504
Drug: R-GemOx
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.
Study: NCT06601504
Drug: HMPL-760 placebo planned dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-760 placebo planned dose 1 daily (QD) orally
Study: NCT06601504
Drug: HMPL-760 planned dose 2
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HMPL-760 planned dose 2 daily (QD) orally
Study: NCT06601504
Drug: HMPL-760 placebo planned dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-760 placebo planned dose 2 daily (QD) orally
Study: NCT05009862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05009862
Drug: Aspirin 81Mg Ec Tab
Normalized name: ASPIRIN 81MG EC TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 81 milligrams
Study: NCT06697106
Drug: Nonsteroidal anti-inflammatory drugs
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo direct vision internal urethrotomy (DVIU) plus nonsteroidal anti-inflammatory drugs (NSAID) for 3 weeks.
Study: NCT06697106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo direct vision internal urethrotomy (DVIU) plus a placebo for 3 weeks.
Study: NCT06698744
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 3 days of intravenous (IV) cyclophosphamide 500 mg/m\^2 days -5 to -3 or -4 to -2 where day 0 is the day of CAR T-cell infusion.
Study: NCT06698965
Drug: Immunotherapy （Envafolimab）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Envafolimab: 300mg, Q3W, subcutaneous injection is administered on day 1 of each cycle.
Study: NCT04794972
Drug: GNC-039
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion.
Study: NCT05786378
Drug: local anesthesia in external auditory canal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local anesthesia cream (lidocaine cream) will be applied in external auditory canal for 15 minutes
Study: NCT05112549
Drug: Nivolumab [Opdivo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (OPDIVO®) is a marketed pharmaceuticals material authorized in the European Union. This study uses an off-label route of administration of nivolumab. Subjects with leptomeningeal disease in solid tumours with an approved indication for intravenous treatment with the PD1 antibody will receive an intrathecal application of nivolumab. A total of six i.th. applications will be performed every 14 days. The intrathecal administration will be performed via an Ommaya reservoir or another intraventricular catheter.
Study: NCT05532501
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer placebo orally, 6 individual 0.1 ml puffs on the tongue (lingual), one every 30 seconds.
Study: NCT05532501
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds
Study: NCT04790331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet
Study: NCT04969666
Drug: IPED2015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment
Study: NCT04969666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04955951
Drug: Topical corticosteroid ointment
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: corticosteroid 1 %.
Study: NCT04983615
Drug: fentanyl-based sedation
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl-based sedation instead of midazolam-based sedation in ventilated patients
Study: NCT04983615
Drug: midazolam-based sedation
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam-based sedation
Study: NCT05179265
Drug: recombinant human serum albumin
Normalized name: RECOMBINANT HUMAN SERUM ALBUMIN ORYZA SATIVA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/bottle (20%, 50 mL)
Study: NCT05770609
Drug: SPH3127 Tablets with Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm description
Study: NCT05770609
Drug: SPH3127 Tablets with Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm description
Study: NCT05770609
Drug: SPH3127 Tablets placebo
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm description
Study: NCT05488405
Drug: Mesalamine Oral Product
Normalized name: mesalamine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine oral suspension for oral use
Study: NCT04968509
Drug: PCSK9 inhibitors and statins with or without ezetimibe
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in experimental group are treated with PCSK9 inhibitors (140mg with Evolocumab or 75mg with Alirocumab or 150mg with Tafolecimab subcutaneously every two weeks) and conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
Study: NCT04968509
Drug: Statins with or without ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in control group are only treated with conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
Study: NCT04813991
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 600 mg for breakthrough pain.
Study: NCT04813991
Drug: OxyCODONE 5 Mg Oral Capsule
Normalized name: oxyCODONE 5 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: OxyCODONE 5 Mg Oral Capsule for breakthrough pain.
Study: NCT05785728
Drug: DB-1202
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered I.V.
Study: 35932699
Drug: Robotic cat
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic cat therapy (20 min/week for 2 months)
Study: 32542352
Drug: Active behavioral
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active behavioral Control Condition (CC)
Study: 34561142
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines
Study: 34751617
Drug: Bevacizumab (BEV)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BEV) treatment
Study: 33721566
Drug: Universal HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal HIV testing and treatment (UTT) via home-based HIV counselling and testing, linkage to care, promotion of ART adherence, and voluntary medical male circumcision.
Study: 38320207
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine
Study: 37422602
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose albumin
Study: 39705390
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin
Study: 32439008
Drug: Selatogrel 8
Normalized name: Selatogrel
DrugBank: Selatogrel (DB15163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selatogrel 8 mg
Study: 34337905
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (60,000 IU of colecalciferol monthly)
Study: 33515070
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin (7.5 mg with dose escalation to 67.5 mg)
Study: 34818575
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (100 mg/kg body weight/day)
Study: 32782111
Drug: Self-acupressure applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-acupressure applied to the TH-6 acupuncture point for 15 min twice a day for one week
Study: 34231532
Drug: Anti-VEGF treatment
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF treatment
Study: 34587383
Drug: REGEN-COV 1200-mg
Normalized name: casirivimab
DrugBank: Casirivimab (DB15941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: REGEN-COV 1200-mg
Study: 35751108
Drug: Upadacitinib (UPA)
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib (UPA) 15 mg/day
Study: 32736891
Drug: Linagliptin 5mg
Normalized name: LINAGLIPTIN 5MG TAB
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin 5mg added to background insulin therapy
Study: 38740499
Drug: Low-dose naltrexone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naltrexone (LDN)
Study: 38151311
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy
Study: 33766820
Drug: Buccal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Buccal midazolam (BM) administered by lay carers
Study: 32985064
Drug: Low-dose THC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose THC (5 or 10 mg)
Study: 39401872
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF)
Study: 33711699
Drug: No G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No G-CSF
Study: 35057489
Drug: 11 g
Normalized name: PSMA-11 Ga 68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 g of BiotisTM GOS
Study: 35867135
Drug: High albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High albumin + IVIG treatment group
Study: 32007523
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light therapy (IPL) - four flashes
Study: 33848338
Drug: Treatment D
Normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment D vs Placebo
Study: 32222589
Drug: Cilostazol and
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol and aspirin
Study: 33040610
Drug: onabotulinumtoxin-A (treatment)
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: onabotulinumtoxin-A (treatment)
Study: 32349156
Drug: Nursing narratives
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing narratives with specific words (e.g., 'urination', 'food supply', 'bowel mobility', 'pain')
Study: 35917774
Drug: Variable-rate infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable-rate infusion of norepinephrine
Study: 35917774
Drug: Fixed-rate infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed-rate infusion of norepinephrine
Study: 34933684
Drug: Inactivated SARS-CoV-2
Normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated SARS-CoV-2 vaccine (0-28 days regimen)
Study: 32408153
Drug: Calorie restriction
Normalized name: Resurrection Lily Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie restriction (daily or intermittently)
Study: 36278416
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group
Study: 32637895
Drug: qHPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: qHPV vaccine
Study: 33169839
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin
Study: 34624497
Drug: Tailored chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored chemotherapy (T), n = 384
Study: 35568881
Drug: Pirfenidone treatment
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone treatment
Study: 35177277
Drug: Olaparib (OLA)
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib (OLA) monotherapy (300 mg tablets, BID)
Study: 35177277
Drug: Olaparib (OLA)
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib (OLA) monotherapy
Study: 35177277
Drug: Olaparib (OLA)
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib (OLA) monotherapy in PSOC
Study: 32845589
Drug: Halobetasol Propionate
Normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol Propionate (HP) 0.01% lotion
Study: 33293172
Drug: Intravenous Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Dexamethasone
Study: 34498056
Drug: Lanraplenib (LANRA)
Normalized name: benzalkonium
DrugBank: Lanraplenib (DB14770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lanraplenib (LANRA) 30 mg once daily for 12 weeks
Study: 39773831
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin
Study: 35017007
Drug: Conventional Radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional Radiation Therapy (cRT)
Study: 35753838
Drug: MR vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR vaccine (separate administration)
Study: 33275769
Drug: Symptomatic patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic patients in need of immediate treatment
Study: 38494574
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine